These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24787067)

  • 1. YKL-40 in pediatric asthma, MUC5B promoter polymorphism in idiopathic pulmonary fibrosis, and esmolol in septic shock.
    Kulkarni HS; Guzy RD; McEvoy C
    Am J Respir Crit Care Med; 2014 May; 189(9):1138-40. PubMed ID: 24787067
    [No Abstract]   [Full Text] [Related]  

  • 2. The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma.
    Konradsen JR; James A; Nordlund B; Reinius LE; Söderhäll C; Melén E; Wheelock AM; Lödrup Carlsen KC; Lidegran M; Verhoek M; Boot RG; Dahlén B; Dahlén SE; Hedlin G
    J Allergy Clin Immunol; 2013 Aug; 132(2):328-35.e5. PubMed ID: 23628340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should β-blockers be used in septic shock?
    Lira A; Pinsky MR
    Crit Care; 2014 May; 18(3):304. PubMed ID: 25033414
    [No Abstract]   [Full Text] [Related]  

  • 4. Is there a role for β-blockade in septic shock?
    Pinsky MR
    JAMA; 2013 Oct; 310(16):1677-8. PubMed ID: 24108438
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-acting β-blocker administration in patients with septic shock.
    Lin GM
    JAMA; 2014 Feb; 311(7):737. PubMed ID: 24549559
    [No Abstract]   [Full Text] [Related]  

  • 6. Short-acting β-blocker administration in patients with septic shock.
    Bouglé A; Mira JP
    JAMA; 2014 Feb; 311(7):736-7. PubMed ID: 24549558
    [No Abstract]   [Full Text] [Related]  

  • 7. Short-acting β-blocker administration in patients with septic shock.
    Sanfilippo F; Santonocito C; Maybauer MO
    JAMA; 2014 Feb; 311(7):736. PubMed ID: 24549557
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-acting β-blocker administration in patients with septic shock.
    Cortés DO; Taccone FS; Vincent JL
    JAMA; 2014 Feb; 311(7):735-6. PubMed ID: 24549556
    [No Abstract]   [Full Text] [Related]  

  • 9. Short-acting β-blocker administration in patients with septic shock--reply.
    Morelli A; Ertmer C; Singer M
    JAMA; 2014 Feb; 311(7):737-8. PubMed ID: 24549560
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.
    Morelli A; Ertmer C; Westphal M; Rehberg S; Kampmeier T; Ligges S; Orecchioni A; D'Egidio A; D'Ippoliti F; Raffone C; Venditti M; Guarracino F; Girardis M; Tritapepe L; Pietropaoli P; Mebazaa A; Singer M
    JAMA; 2013 Oct; 310(16):1683-91. PubMed ID: 24108526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study.
    Morelli A; Singer M; Ranieri VM; D'Egidio A; Mascia L; Orecchioni A; Piscioneri F; Guarracino F; Greco E; Peruzzi M; Biondi-Zoccai G; Frati G; Romano SM
    Intensive Care Med; 2016 Oct; 42(10):1528-1534. PubMed ID: 27101380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Possible Pathogenesis of Idiopathic Pulmonary Fibrosis considering
    Zhang Q; Wang Y; Qu D; Yu J; Yang J
    Biomed Res Int; 2019; 2019():9712464. PubMed ID: 31309122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esmolol for septic shock: more than just heart rate control?
    Orbegozo Cortes D; Njimi H; Dell'Anna AM; Taccone FS
    Minerva Anestesiol; 2014 Feb; 80(2):254-8. PubMed ID: 24500140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC5B promoter polymorphism and pulmonary fibrosis.
    Burch LH
    N Engl J Med; 2011 Jul; 365(2):178; author reply 178-9. PubMed ID: 21751916
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.
    Peljto AL; Zhang Y; Fingerlin TE; Ma SF; Garcia JG; Richards TJ; Silveira LJ; Lindell KO; Steele MP; Loyd JE; Gibson KF; Seibold MA; Brown KK; Talbert JL; Markin C; Kossen K; Seiwert SD; Murphy E; Noth I; Schwarz MI; Kaminski N; Schwartz DA
    JAMA; 2013 Jun; 309(21):2232-9. PubMed ID: 23695349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A common MUC5B promoter polymorphism and pulmonary fibrosis.
    Seibold MA; Wise AL; Speer MC; Steele MP; Brown KK; Loyd JE; Fingerlin TE; Zhang W; Gudmundsson G; Groshong SD; Evans CM; Garantziotis S; Adler KB; Dickey BF; du Bois RM; Yang IV; Herron A; Kervitsky D; Talbert JL; Markin C; Park J; Crews AL; Slifer SH; Auerbach S; Roy MG; Lin J; Hennessy CE; Schwarz MI; Schwartz DA
    N Engl J Med; 2011 Apr; 364(16):1503-12. PubMed ID: 21506741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC5B promoter polymorphism and pulmonary fibrosis.
    Zhang GY; Liao T; Gao WY
    N Engl J Med; 2011 Jul; 365(2):178; author reply 178-9. PubMed ID: 21751917
    [No Abstract]   [Full Text] [Related]  

  • 18. MUC5B Promoter Variant rs35705950 Affects MUC5B Expression in the Distal Airways in Idiopathic Pulmonary Fibrosis.
    Nakano Y; Yang IV; Walts AD; Watson AM; Helling BA; Fletcher AA; Lara AR; Schwarz MI; Evans CM; Schwartz DA
    Am J Respir Crit Care Med; 2016 Feb; 193(4):464-6. PubMed ID: 26871673
    [No Abstract]   [Full Text] [Related]  

  • 19. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis.
    Zhang Y; Noth I; Garcia JG; Kaminski N
    N Engl J Med; 2011 Apr; 364(16):1576-7. PubMed ID: 21506748
    [No Abstract]   [Full Text] [Related]  

  • 20. MUC5B Promoter Polymorphism and Survival in Indian Patients With Idiopathic Pulmonary Fibrosis.
    Dhooria S; Bal A; Sehgal IS; Prasad KT; Kashyap D; Sharma R; Muthu V; Agarwal R; Aggarwal AN
    Chest; 2022 Oct; 162(4):824-827. PubMed ID: 35405109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.